Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
United States
University of Alabama O'Neal Cancer Center, Birmingham, Alabama UCLA, Los Angeles, California University of Miami Health System, Miami, Florida Moffitt Cancer Center, Tampa, Florida Emory University Hospital, Atlanta, Georgia